SRPT News and Press, Sarepta Therapeutics Inc. From 06/21/24

2024-06-21 10:03:58 ET More on Catalent Catalent shareholders approve acquisition by Novo Holdings Catalent, Novo Nordisk receive FTC request for more information Seeking Alpha’s Quant Rating on Catalent Historical earnings data for Catalent Fi...

A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 2.7% to $127.255 on volume of 88,797,787 shares Ascent Solar Technologies Inc (ASTI) rose 9.6% to $0.1183 on volume of 88,651,038 shares Crown Electrokinetics Corp. (CRKN) fell 19.0% to $0.040499 on volu...

2024-06-21 09:12:53 ET More on Solid Biosciences Buy Solid Biosciences: Unpacking Its Main Value Driver Solid Biosciences gets FDA rare pediatric disease status for DMD therapy William Blair starts Solid Biosciences at outperform Seeking Alpha’s Quant ...

2024-06-21 08:15:07 ET Goldman Sachs analyst issues BUY recommendation for SRPT on June 21, 2024 07:05AM ET. The previous analyst recommendation was Buy. SRPT was trading at $123.5 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current a...

2024-06-21 05:30:35 ET More on related stocks: Smith & Wesson Brands, Inc. (SWBI) Q4 2024 Earnings Call Transcript Asana: Don't Buy This Dip, Part 2 Asana, Inc. (ASAN) Q1 2025 Earnings Call Transcript Asana reiterates guidance, unveils $150M buyback ...

2024-06-20 20:30:02 ET Morgan Stanley analyst issues OVERWEIGHT recommendation for SRPT on June 20, 2024 07:15PM ET. The previous analyst recommendation was Overweight. SRPT was trading at $123.5 at issue of the analyst recommendation. The overall analyst consensus : BUY...

2024-06-20 17:31:25 ET More on Sarepta Therapeutics Sarepta Therapeutics: Navigating Elevidys Upside Potential Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy Sarepta gains aft...

– FDA grants traditional approval to ELEVIDYS for ambulatory Duchenne patients – FDA grants accelerated approval to ELEVIDYS for non-ambulatory Duchenne patients – Sarepta will host an investor conference call on June 21, 2024, at 8:30 a.m. ET ...

2024-06-17 13:44:12 ET Summary Capricor Therapeutics, Inc.'s rolling BLA submission of CAP-1002 for the treatment of patients with DMD, expected in Q3 of 2024. Top-line results from Cohort A of the phase 3 HOPE-3 study, using CAP-1002 for the treatment of patients with DMD, expect...

2024-06-17 13:29:18 ET Summary Sarepta Therapeutics submitted a request to the FDA for label expansion of Elevidys, with a response expected by June 21st. Roche initiated the process for Elevidys marketing authorization application in Europe, expected to be completed by H1 2024. ...